Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer

Clinical Cancer Research

Volumn 20, Issue 12, 2014, Pages 3280-3288

  Tucker, Susan L ^a   Gharpure, Kshipra ^a   Herbrich, Shelley M ^a   Unruh, Anna K ^a   Nick, Alpa M ^a   Crane, Erin K ^a   Coleman, Robert L ^a   Guenthoer, Jamie ^b   Dalton, Heather J ^a   Wu, Sherry Y ^a   Rupaimoole, Rajesha ^a   Lopez Berestein, Gabriel ^a   Ozpolat, Bulent ^a   Ivan, Cristina ^a   Hu, Wei ^a   Baggerly, Keith A ^a   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FATTY ACID BINDING PROTEIN 4; ADH1B PROTEIN, HUMAN; ALCOHOL DEHYDROGENASE; FABP4 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN; MESSENGER RNA; TUMOR MARKER;

ADH1B GENE; ARTICLE; DISEASE ASSOCIATION; FABP4 GENE; FEMALE; GENE; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC CORRELATION; GENETIC SELECTION; HIGH RISK PATIENT; HUMAN; INCIDENCE; MINIMAL RESIDUAL DISEASE; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; CANCER GRADING; COHORT ANALYSIS; CYSTADENOCARCINOMA, SEROUS; CYTOREDUCTIVE SURGERY; FOLLOW UP; GENETICS; MORTALITY; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

ALCOHOL DEHYDROGENASE; BIOMARKERS, TUMOR; COHORT STUDIES; CYSTADENOCARCINOMA, SEROUS; CYTOREDUCTION SURGICAL PROCEDURES; FATTY ACID-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOPLASM GRADING; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE;

EID: 84902661644     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0445     Document Type: Article

References (26)

1. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 2006;107:77-85.
2. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup. J Clin Oncol 2009;27:1419-25.
3. Chang SJ, Bristow RE, Ryu HS. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol 2012;19:4059-67.
4. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009;115:1234-44.
5. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-59. (Pubitemid 34177431)
6. Ferrandina G, Sallustio G, Fagotti A, Vizzielli G, Paglia A, Cucci E, et al. Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial. Br J Cancer 2009;101:1066-73.
7. Rodriguez N, Rauh-Hain JA, Shoni M, Berkowitz RS, Muto MG, Feltmate C, et al. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol 2012;125:362-6.
8. Angioli R, Plotti F, Capriglione S, Aloisi A, Montera R, Luvero D, et al. Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? Gynecol Oncol 2013;128:579-83.
9. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
10. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008;14:5198-208.
11. Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, Bogomolniy F, et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 2008;68:5478-86.
12. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
13. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-93. (Pubitemid 36181903)
14. Ruijter JM, Ramakers C, Hoogaars WMH, Karlen Y, Bakker O, van den Hoff MJB, et al. Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Res 2009;37:e45.
15. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and power-ful approach to multiple testing. J R Stat Soc B 1995;57:289- 300.
16. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011;17:1498-503.
17. Leek JT, Scharpf RB, Bravo HC, Simcha D, Langmead B, Johnson WE, et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet 2010;11:733-9.
18. Kernagis DN, Hall AH, Datto MB. Genes with bimodal expression are robust diagnostic targets that define distinct subtypes of epithelial ovarian cancer with different overall survival. J Mol Diagn 2012;14:214-22.
19. Wang J, Wen S, Symmans WF, Pusztai L, Coombes KR. The bimodality index: a criterion for discovering and ranking bimodal signatures from cancer gene expression profiling data. Cancer Inform 2009;7:199-216.
20. Zilliox MJ, Irizarry RA. A gene expression bar code for microarray data. Nat Methods 2007;4:911-3. (Pubitemid 350042377)
21. Elmasri H, Karaaslan C, Teper Y, Ghelfi E, Weng M, Ince TA, et al. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J 2009;23:3865-73.
22. Kajimoto K, Takayanagi S, Sasaki S, Akita H, Harashima H. RNA interference-based silencing reveals the regulatory role of fatty acid-binding protein 4 in the production of IL-6 and vascular endothelial growth factor in 3T3-L1 adipocytes. Endocrinology 2012;153:5629-36.
23. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011;11:719-25.
24. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943-53.
25. Axtell AE, Lee MH, Bristow RE, Dowdy SC, Cliby WA, Raman S, et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol 2007;25:384-9. (Pubitemid 350002986)
26. Kang S, Kim TJ, Nam BH, Seo SS, Kim BG, Bae DS, et al. Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis. J Surg Oncol 2010;101:13-7.